Cas:954236-13-6 4-bromo-1-(difluoromethoxy)-2-(trifluoromethyl)benzene manufacturer & supplier

We serve Chemical Name:4-bromo-1-(difluoromethoxy)-2-(trifluoromethyl)benzene CAS:954236-13-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-bromo-1-(difluoromethoxy)-2-(trifluoromethyl)benzene

Chemical Name:4-bromo-1-(difluoromethoxy)-2-(trifluoromethyl)benzene
CAS.NO:954236-13-6
Synonyms:4-bromo-1-difluoromethoxy-2-trifluoromethyl-benzene
Molecular Formula:C8H4BrF5O
Molecular Weight:291.01300
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:9.23000
Exact Mass:289.93700
LogP:4.06930

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-bromo-1-difluoromethoxy-2-trifluoromethyl-benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-bromo-1-difluoromethoxy-2-trifluoromethyl-benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-bromo-1-difluoromethoxy-2-trifluoromethyl-benzene Use and application,4-bromo-1-difluoromethoxy-2-trifluoromethyl-benzene technical grade,usp/ep/jp grade.


Related News: GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.�� 4-bromo-1-(difluoromethoxy)-2-(trifluoromethyl)benzene manufacturer The FDA said its decision allows for the J&J doses to be used in the United States or exported. T 4-bromo-1-(difluoromethoxy)-2-(trifluoromethyl)benzene supplier Any US citizen who has been in the Hubei province in the last 14 days will be subject to up to 14 days of mandatory quarantine upon return to the United States. 4-bromo-1-(difluoromethoxy)-2-(trifluoromethyl)benzene vendor GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.�� 4-bromo-1-(difluoromethoxy)-2-(trifluoromethyl)benzene factory A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.